Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to see how well revumenib works when given with chemotherapy to treat infant leukemia. The children in this study have acute leukemia that came back or keeps growing even after treatment. The leukemia has a gene rearrangement (genetic change) called KMT2A-R.
Researchers want to see if adding radiation therapy to standard medical treatments works better than standard therapies alone in people with kidney cancer. The standard therapies include:
Mycosis fungoides (MF) is a disease in which lymphocytes (a type of white blood cell) become cancerous and affect the skin, causing cutaneous T-cell lymphoma. The drug bexarotene and a very low-dose form of radiation treatment called total skin electron beam (TSEB) radiotherapy are each used individually to treat MF; this study is evaluating the safety of their use together. Researchers think that since bexarotene takes up to three months to relieve symptoms, combining it with TSEB could stabilize or improve MF and reduce symptoms, including itching.
Researchers want to find the best dose of AJ1-11095 to treat myelofibrosis. The people in this study have myelofibrosis that came back or got worse after treatment.
Researchers want to find the best dose of ODM-212 to treat advanced solid tumors. The people in this study have solid tumors that have spread and cannot be cured with standard therapies. Examples include:
Researchers want to find the best dose of DCC-3009 to use in people with gastrointestinal stromal tumors (GIST). The people in this study have GIST that has metastasized (spread) after treatment. In addition, their cancers have a mutation (change) in the KIT or PDGFRA gene. These mutations are common in people with GIST and can cause cancer to grow.
Researchers are assessing trametinib and azacitidine alone and with other drugs to treat leukemia in young people. The people in this study have newly diagnosed juvenile myelomonocytic leukemia (JMML).
Rhabdomyosarcoma (RMS) is a type of cancer that occurs in the soft tissues in the body. Researchers in this study are comparing different chemotherapy-based treatments for children and young adults with very low-risk RMS, low-risk RMS, and RMS with DNA mutations, with treatment tailored to the predicted aggressiveness of each patient's cancer. The standard chemotherapy drugs participants will receive include vincristine, dactinomycin, and cyclophosphamide.
